Interleukin-6 inhibition and cardiovascular disease in patients with rheumatoid arthritis

Abstract


Rheumatoid arthritis (RA) is a disease conferring a high risk for cardiovascular events (CVE). Systemic inflammation underlying RA favors the development of CVE. The safety of biological agents acting on the cardiovascular system has been inadequately investigated. On the one hand, they decrease RA activity and, on the other, may increase the risk of CVE. This review analyzes the literature data predominantly published in recent years on the effect of an IL-6 receptor inhibitor on the cardiovascular system. Tocilizumab is shown to be a promising agent to reduce cardiovascular risk. The findings need to be clinically verified. Long-term prospective investigations should be conducted to determine more exactly the impact of IL-6 receptor inhibition on the development of CVE.

References

  1. Попкова Т.В., Новикова Д.С., Насонов Е.Л. Атеросклероз при ревматических заболеваниях. В кн.: Ревматология: клинические рекомендации. М.: ГЭОТАР-Медиа; 2010
  2. Peters MJ, Symmons DP, McCarey D et al. EULAR evidencebased recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325-331. doi: 10.1136/ard.2009.113696.
  3. Gabriel SE. Why do people with rheumatoid arthritis still die prematurely? Ann Rheum Dis. 2008;67(Suppl 3):iii30-34. doi: 10.1136/ard.2008.098038.
  4. Meune C, Touze E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in RA: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis. 2010;103(4):253-261. doi: 10.1016/j.acvd.2010.03.007.
  5. Фоломеева О.М., Галушко Е.А., Эрдес Ш.Ф. Распространенность ревматических заболеваний в популяциях взрослого населения России и США. Научно-практическая ревматология. 2008;47(4):4-13. doi: 10.14412/1995-4484-2008-529.
  6. Van Halm VP, Peters MJ, Voskuyl AE et al. Rheumatoid arthritis versus type 2 diabetes as a risk factor for cardiovascular disease: a cross-sectional study. Ann Rheum Dis. 2009;68(9):1395-1400. doi: 10.1136/ard.2008.094151.
  7. Holmqvist ME, Wedren S, Jacobsson LT et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med. 2010;268(6):578-885. doi: 10.1111/j.1365-2796.2010.02260.x.
  8. Van Leuven SI, Franssen R, Kastelein JJ et al. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford). 2008;47(1):3-7. doi: 10.1093/rheumatology/kem202.
  9. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-116.
  10. McInnes IB, Shett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205-2219. doi: 10.1056/NEJMra1004965.
  11. Новиков А.А., Александрова Е.Н., Диатроптова М.А., Насонов Е.Л. Роль цитокинов в патогенезе ревматоидного артрита. Научно-практическая ревматология. 2010;2:71-82. doi: 10.14412/1995-4484-2010-1420.
  12. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Под ред. Насонова Е.Л. М.: ИМА-Пресс; 2013.
  13. Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J. 2000;21(19):1574-1583.
  14. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens. 2003;21(10):1787-1803.
  15. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.
  16. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford). 2010;49(1): 15-24. doi: 10.1093/rheumatology/kep329.
  17. Henry RM. Interleukin 6 as therapeutic target in athero-/arteriosclerosis-small steps towards a new treatment paradigm in cardiovascular disease. Atherosclerosis. 2011;219(2):390-391. doi: 10.1016/j.atherosclerosis.2011.07.102.
  18. Gotsman I, Stabholz A, Planer D et al. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden? Isr Med Assoc J. 2008;10(7):494-498.
  19. Ridker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014;35(27):1782-1791. doi: 10.1093/eurheartj/ehu203
  20. Cheng HF, Feng Y, Jiang DM, Tao KY, Kong MJ. Protective function of tocilizumab in human cardiac myocytes ischemia reperfusion injury. Asian Pac J Trop Med. 2015;8(1):48-52. doi: 10.1016/S1995-7645(14)60186-3.
  21. Sack U, Kinne RW, Marx T. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int. 1993;13(2):45-51.
  22. Madhok R, Crilly A, Watson J. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52(3):232-234.
  23. Bermudez EA, Rifai N, Buring J et al. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol. 2002;22(10):1668-1673.
  24. Fernandez-Real JM, Vayreda M, Richart C et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001;86(3):1154-1159.
  25. Brady SR, de Courten B, Reid CM. The role of traditional cardiovascular risk factors among patients with rheumatoid arthritis. J Rheumatol. 2009;36(1):34-40.
  26. Dessein PH, Joffe BI. Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis. Clin Exp Rheumatol. 2006;24(2):161-167.
  27. Esteve E, Castro A, López-Bermejo A et al. Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity. Diabetes Care. 2007;30(4):939-945.
  28. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension. 2005;46(5): 1118-1122.
  29. Попкова Т.В., Новикова Д.С., Насонов Е.Л. Интерлейкин 6 и сердечно-сосудистая патология при ревматоидном артрите. Научно-практическая ревматология. 2011;49(4):64-72. doi: 10.14412/1995-4484-2011-63.
  30. Humphries SE, Luong LA, Ogg MS et al. The interleukin-6-174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J. 2001;22(24):2243-2252.
  31. Brull DJ, Montgomery HE, Sanders J et al. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol. 2001;21(9):1458-1463.
  32. Aker S, Bantis C, Reis P et al. Influence of interleukin-6 G-174C gene polymorphism on coronary artery disease, cardiovascular complications and mortality in dialysis patients. Nephrol Dial Transplant. 2009;24(9):2847-2851. doi: 10.1093/ndt/gfp141.
  33. Gaudino M, Andreotti F, Zamparelli R et al. The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation. 2003;9(108) Suppl. 1:195-199.
  34. Swerdlow DI, Holmes MV, Kuchenbaecker KB et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomization analysis. Lancet. 2012;379(9822): 1214-1224. doi: 10.1016/S0140-6736(12)60110-X.
  35. Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS et al. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis. 2009;204(1): 178-183. doi: 10.1016/j.atherosclerosis.2008.08.036.
  36. Palomino-Morales R, Gonzalez-Juanatey C, Vazquez-Rodriguez TR et al. Interleukin-6 gene -174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2009;27(6):964-970.
  37. Sarwar N, Butterworth A, John Danesh J. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379(9822):1205-1213. doi: 10.1016/S0140-6736(11)61931-4
  38. del Rincón ID, Williams K, Stern MP et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthr Rheum. 2001;44(12):2737-2745.
  39. Dessein PH, Joffe BI, Veller MG et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol. 2005;32(3):435-442.
  40. Sattar N, Crompton P, Cherry L. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis rheum. 2007;56:831-839.
  41. Daïen CI, Duny Y, Barnetche T, Daurès JP, Combe B, Morel J. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis. 2012;71(6):862-868. doi: 10.1136/annrheumdis-2011-201148
  42. Попкова Т.В., Новикова Д.С., Новиков А.А., и др. Роль нарушений в системе транспорта холестерина крови в развитии атеросклероза при ревматоидном артрите. Научно-практическая ревматология. 2007;5:4-10. doi: 10.14412/1995-4484-2007-14.
  43. Ettinger WH, Varma VK, Sorci-Thomas M et al. Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler Thromb. 1994;14(1):8-13.
  44. Khovidhunkit W, Kim MS, Memon RA. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45:1169-1196.
  45. Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J. 2000;21(19):1574-1583.
  46. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009;68(4):460-469. doi: 10.1136/ard.2008.101964.
  47. Singh U, Dasu MR, Yancey PG, Afify A, Devaraj S, Jialal I. Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res. 2008;49(5):1015-1023. doi: 10.1194/jlr.M700535-JLR200.
  48. Navab M, Berliner JA, Subbanagounder G et al. HDL and inflammatory response induced by LDL-derived oxidized phospholipids. Arteriol Thromb Vasc Biol. 2001;21:481-488.
  49. McMahon M, Grossman J, FitzGerald J. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006;54:2541-2549.
  50. Watanabe J, Charles-Schoeman C, Miao Y, Elashoff D, Lee YY, Katselis G, Lee TD, Reddy ST. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum. 2012;64(6):1828-1837. doi: 10.1002/art.34363
  51. Burger D, Dayer JM. High-density lipoprotein-associated apolipoprotein A-1: the missing link between infection and chronic inflammation? Autoimmun Rev. 2002;1:111-117.
  52. Lourida ES, Georgiadis AN, Papavasiliou EC et al. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2. Arthritis Res. Ther. 2007;9:19.
  53. Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, FitzGerald J, Ranganath VK, Taylor M, McMahon M, Paulus HE, Reddy ST. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis. 2012;71(7):1157-1162. doi: 10.1136/annrheumdis-2011-200493.
  54. Raterman HG, Levels H, Voskuyl AE, Lems WF, Dijkmans BA, Nurmohamed MT. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann Rheum Dis. 2013;72(4):560-565. doi: 10.1136/annrheumdis-2011-201228.
  55. Jamnitski A, Levels JH, van den Oever IA, Nurmohamed MT. High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a cohort study. J Rheumatol. 2013;40(6):825-830. doi: 10.3899/jrheum.121358.
  56. Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, Gabriel SE. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70(3):482-487. doi: 10.1136/ard.2010.135871.
  57. Zhang J, Chen L, Delzell E, Muntner P, Hillegass WB, Safford MM, Millan IY, Crowson CS, Curtis JR. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis. 2014;73(7):1301-1308. doi: 10.1136/annrheumdis-2013-204715.
  58. Navarro-Millán I, Yang S, DuVall SL, Chen L, Baddley J, Cannon GW, Delzell ES, Zhang J, Safford MM, Patkar NM, Mikuls TR, Singh JA, Curtis JR. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. Ann Rheum Dis. 2015 Jan 21. pii: annrheumdis-2013-204987. doi: 10.1136/annrheumdis-2013-204987.
  59. Насонов Е.Л. Новые возможности фармакотерапии ревматических болезней — ингибирование интерлейкина-6. Клиническая фармакология и терапия. 2008;17(1):2-8.
  60. Curtis JR, Perez-Gutthann S, Suissa S, Napalkov P, Singh N, Thompson L, Porter-Brown B; Actemra Pharmacoepidemiology Board Tocilizumab in rheumatoidd arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources. Semin Arthritis Rheum. 2015;44(4):381-388. doi: 10.1016/j.semarthrit.2014.07.006.
  61. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Sano Y, Yaguramaki H, Yamanaka H. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol. 2014;41(1):15-23. doi: 10.3899/jrheum.130466.
  62. Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5):R141. doi: 10.1186/ar3455.
  63. Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gómez-Reino J, Sebba A, Pilson R, Williams S, Van Vollenhoven R. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol. 2013;40(6):768-80. doi: 10.3899/jrheum.120687.
  64. Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516-1523.
  65. Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968-2980.
  66. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987-997.
  67. Maini RN, Taylor PC, Szechinski J et al. Double blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817-2829.
  68. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol. 2010;20:222-232. doi: 10.1007/s10165-010-0279-5.
  69. Kawashiri SY, Kawakami A, Yamasaki S et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int. 2011;31: 451-456. doi: 10.1007/s00296-009-1303-y.
  70. Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162-1167.
  71. Gabay C, Emery P, van Vollenhoven R et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381:1541-1550. doi: 10.1016/S0140-6736(13)60250-0.
  72. Souto A, Salgado E, Maneiro JR, Mera A, Carmona L, Gómez-Reino JJ. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheum. 2015;67(1):117-127. doi: 10.1002/art.38894.
  73. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
  74. Sniderman AD, Jungner I, Holme I, Aastveit A, Walldius G. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. J Intern Med. 2006;259:455-461.
  75. Chen DY, Chen YM, Hsieh TY, Hsieh CW, Lin CC, Lan JL Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17:52. doi: 10.1186/s13075-015-0559-8.
  76. McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Carlson TH, Delles C, Lee JS, Sattar N. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74(4):694-702. doi: 10.1136/annrheumdis-2013-204345.
  77. Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W, Laudes M. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One. 2010;5(12):e14328. doi: 10.1371/journal.pone.0014328.
  78. Sattar N, Lee JS, Rowell L, McInnes I. Tocilizumab-induced alteration in lipid and apolipoprotein levels correlate with changes in clinical inflammatory markers in rheumatoid arthritis (RA). Ann Rheum Dis. 2011;70(Suppl.3):588.
  79. Rao VU, Pavlov A, Klearman M, Musselman D, Giles JT, Bathon JM, Sattar N, Lee JS. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheum. 2015;67(2):372-380. doi: 10.1002/art.38920.
  80. Попкова Т.В., Новикова Д.С., Панасюк Е.Ю. и др. Влияние тоцилизумаба на систему транспорта холестерина крови и ранние проявления атеросклероза у больных ревматоидным артритом. Терапевтический архив. 2012;5:9-18.
  81. McInnes I, Lee JS, Wu W et al. Translational, Randomized, Placebo (PBO)-Controlled Study to evaluate the effects of tocilizumab (TCZ) on parameters of lipids and inflammation. Ann Rheum Dis. 2011;70(suppl 3):73.
  82. Bisoendial R, Stroes E, Kastelein J et al. Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins. Nat Rev Rheumatol. 2010;6:157-164. doi: 10.1038/nrrheum.2009.277.
  83. Насонов Е.Л. Перспективы применения статинов в ревматологии. РМЖ. 2003;11:1273-1276.
  84. Abeles AM, Pillinger M. Statins as antiinfammatory and immunomodulatory agents. A future in rheumatologic therapy? Arthritis rheumatism. 2006;54:393-407.
  85. Новикова Д.С., Попкова Т.В., Насонов Е.Л. Снижение кардиоваскулярного риска при ревматоидном артрите: двойная польза статинов. Научно-практическая ревматология. 2010; 6:35-38. doi: 10.14412/1995-4484-2010-826.
  86. Lazzerini PE, Lorenzini S, Selvi E et al. Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1β-stimulated synoviocytes from rheumatoid arthritis patients. Clin Exp Rheum. 2007;25:696-700.
  87. Yokota K, Mioyoshi F, Myazaki K et al. High concentration simvastatin induces apoptosis in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol. 2008;35:193-200.
  88. Насонов Е.Л. Применение тоцилизумаба (Актемры) при ревматоидном артрите. Научно-практическая ревматология. 2009;3:18-35.
  89. Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5): 735-740. doi: 10.1038/clpt.2011.35.
  90. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, Kishimoto T. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1):12-19. doi: 10.1007/s10165-008-0125-1.
  91. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88-96. doi: 10.1136/ard.2008.105197.
  92. Genovese M, Smolen JS, Emery P et al. Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis with elevated low-density lipoprotein cholesterol analysis of five phase 3 clinical trials. Program and abstracts of the American College of Rheumatology (ACR) 2008 Annual Scientific Meeting: October 24—29, 2008; San Francisco, California, Abstract 1672.
  93. Kume K, Amano K, Yamada S et al. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol. 2011;38:2169-2171. doi: 10.3899/jrheum.110340.
  94. Protogerou AD, Zampeli E, Fragiadaki K, Stamatelopoulos K, Papamichael C, Sfikakis PP. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis. 2011;219(2):734-736. doi: 10.1016/j.atherosclerosis.2011.09.015.
  95. Moriyama M, Sato M, Sumita Y et al. Tocilizumab increase serum lipids but does not promote arteriosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(Suppl 3):612.
  96. Kobayashi H, Kobayashi Y, Giles JT et al. Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging. J Rheumatol. 2014;41(10):1916-1921. doi: 10.3899/jrheum.131540.
  97. Giles JT, Fernandes V, Lima JA. et al. Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. Arthritis Res Ther. 2005;7(5):195-207.
  98. Davis JM, Knutson KL, Strausbauch MA. A signature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis. Arthritis Rheum. 2011;63(6):1497-1506. doi: 10.1002/art.30323.
  99. Cheng HF, Feng Y, Jiang DM. et al. Protective function of tocilizumab in human cardiac myocytes ischemia reperfusion injury. Asian Pac J Trop Med. 2015:48-52. doi: 10.1016/S1995-7645(14)60186-3.
  100. Lazzerini PE, Capecchi PL, Acampa M et al. Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation. Autoimmun Rev. 2014:936-944. doi: 10.1016/j.autrev.2014.05.007.
  101. van den Oever IA, Sattar N, Nurmohamed MT. Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. Ann Rheum Dis. 2014:954-957. doi: 10.1136/annrheumdis-2013-204767.
  102. Ingegnoli F, Fantini F, Favalli EG et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun. 2008;31:175-179.
  103. Makrilakis K, Fragiadaki K, Smith J et al. Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade. Clin Rheumatol. 2015:419-427. doi: 10.1007/s10067-014-2704-1.

Statistics

Views

Abstract - 152

PDF (Russian) - 24

Cited-By


Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Popkova T.V., Novikova D.S., Nasonov E.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies